-
1 Comment
Avidity Biosciences, Inc is currently in a long term downtrend where the price is trading 12.5% below its 200 day moving average.
From a valuation standpoint, the stock is 94.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 71.5.
Avidity Biosciences, Inc's total revenue rose by 48.2% to $2M since the same quarter in the previous year.
Its net income has dropped by 56.5% to $-16M since the same quarter in the previous year.
Finally, its free cash flow fell by 160.5% to $-13M since the same quarter in the previous year.
Based on the above factors, Avidity Biosciences, Inc gets an overall score of 2/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US05370A1088 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 4B |
|---|---|
| PE Ratio | None |
| Target Price | 66.5556 |
| Beta | 0.91 |
| Dividend Yield | None |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RNA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
